ASH 2022 | Treatment strategies for patients with AML who possess a FLT3 mutation
In this video, Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses the impact of FLT3 mutations on the outcomes of patients with acute myeloid leukemia (AML), and various treatment strategies for these patients. Dr de Botton first highlights the importance of using FLT3 inhibitors, such as midostaurin or quizartinib, when treating these patients, and then comments on the role of stem cell transplantation followed by maintenance therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Grant/Research Support: Forma, Auron, Foghorn,
Consultant: Forma, Auron, Servier, BMS, AbbVie, Jazz, Astellas
Speaker’s bureau: Forma, Auron, Servier, BMS, AbbVie, Jazz, Astellas
